Nuvectis Pharma, Inc.
NASDAQ:NVCTBiotechnology
+$0.39 today
- Market cap
- $697.75M
- Beta
- -0.07
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$1.16
Volume 0.19M
Average 0.08M
NVCT Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Nuvectis Pharma, Inc.NASDAQ: NVCT
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q1 FY2026 selling, general & admin of $2.15M rose 14.1% year over year, behind the +36.8% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 14.9% from the prior quarter. Over 3 fiscal years it compounded at +16.2% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 5 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +36.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $2.15M-14.9% QoQ
- Last fiscal yearDec 2025
- $9.42M+36.0% YoY
- LTMMar 2026
- $9.69M+36.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +14.1% | -100.0% | -114.1 pp |
| 1 year | +36.0% | -100.0% | -136.0 pp |
| 3-year CAGR | +16.2% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 9.42M USD
- Year-over-year change
- +36.0%
- 4-year CAGR
- +29.5%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.42M | +36.0% |
| FY2024 | 2024-12-31 | 6.93M | -7.8% |
| FY2023 | 2023-12-31 | 7.52M | +25.1% |
| FY2022 | 2022-12-31 | 6.01M | +79.4% |
| FY2021 | 2021-12-31 | 3.35M | — |
Selling, General & Admin vs competitors
How NVCT compares with its peers on the latest reported figures
- NVCT's LTM Mar 2026 selling, general & admin of $9.69M is the lowest of the 11 companies compared; the peer median is $40.36M.
- Its year-over-year change of +36.8% is the 3rd highest of 11, against a peer median of +19.7%.
- Over three fiscal years its annual growth of +16.2% compares with a peer median of +18.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $4.7B | +29505.3% | +3.5% | — | |
| LTM Mar 2026 | $176.24M | +26.9% | +75.5% | 81.2% | |
| LTM Jun 2026 | $158.59M | +32.6% | +68.1% | 93.3% | |
| LTM Mar 2026 | $88.42M | +83.1% | +48.1% | 178.3% | |
| LTM Mar 2026 | $42.56M | -1.1% | +23.3% | 196.9% | |
| LTM Mar 2026 | $38.15M | -27.9% | -12.7% | 24.3% | |
| LTM Mar 2026 | $33.29M | +12.6% | +9.8% | — | |
| LTM Mar 2026 | $19.76M | -28.1% | -0.2% | 3951.0% | |
| LTM Mar 2026 | $18.51M | +10.2% | +13.1% | — | |
| LTM Mar 2026 | $15.81M | +34.6% | +50.4% | — | |
| LTM Mar 2026 | $9.69M | +36.8% | +16.2% | — | |
| Peer median (excluding NVCT) | $40.36M | +19.7% | +18.2% | 135.8% | |
Competitors are the stored peer set for NVCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 9.55M | 13.23M | 15.38M | 12.92M | 18.15M |
| Selling, General & Admin | 3.35M | 6.01M | 7.52M | 6.93M | 9.42M |
| Operating Expenses | 12.89M | 19.23M | 22.9M | 19.85M | 27.57M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| EBITDA | (12.89M) | (19.09M) | (22.26M) | (19M) | (26.44M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (12.89M) | (19.23M) | (22.9M) | (19.85M) | (27.57M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 4K | 149K | 637K | 847K | 1.13M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4K | 149K | 637K | 847K | 1.13M |
| Income Before Tax | (12.89M) | (19.09M) | (22.26M) | (19M) | (26.44M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (12.89M) | (19.09M) | (22.26M) | (19M) | (26.44M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.09) | (1.51) | (1.43) | (1.11) | (1.32) |
| EPS (Diluted) | (1.09) | (1.51) | (1.43) | (1.11) | (1.32) |
| Weighted Avg Shares | 12.72M | 12.66M | 15.56M | 17.11M | 21.81M |
| Weighted Avg Shares (Diluted) | 12.72M | 12.66M | 15.56M | 17.11M | 21.81M |
Nuvectis Pharma, Inc.
NASDAQ:NVCT
Intrinsic Alpha fair value
Locked
Current Price
$20.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.